Suspension of trading
Acorda Therapeutics Stock OTC Markets
Stocks
ACOR
US00484M7002
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
OTC Markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-10.00% | -99.91% |
| 24-08-13 | First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc. | CI |
| 24-08-07 | Modified First Amended Joint Liquidation Plan Approved for Acorda Therapeutics, Inc. | CI |
| 1 week | -10.00% | ||
| 1 month | -87.85% | ||
| 3 months | -98.41% | ||
| 6 months | -99.90% | ||
| Current year | -99.91% |
| 1 week | 0 |  | 0.02 |
| 1 month | 0 | | 0.15 |
| 3 years | 0 | | 99.8 |
| 5 years | 0 | | 535.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sofia Ali
COO | Chief Operating Officer | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -10.00% | -99.92% | -99.98% | 16.77K | |
| -3.00% | +2.27% | +73.26% | +113.08% | 72.12B | |
| +1.90% | +23.53% | +59.48% | +94.94% | 65.85B | |
| +5.12% | +25.22% | +5.13% | -5.23% | 29.28B | |
| +0.55% | +1.64% | -4.63% | +469.35% | 27.47B | |
| +2.74% | +12.98% | +54.92% | +24.09% | 26.7B | |
| +0.47% | +6.12% | +37.01% | -16.17% | 20.06B | |
| +1.82% | -6.67% | +251.36% | +388.91% | 18.22B | |
| +0.94% | +3.36% | +15.30% | +581.01% | 16.4B | |
| +0.73% | +5.54% | +39.99% | +148.64% | 13.4B | |
| Average | +1.25% | +8.36% | +43.19% | +169.86% | 32.17B | |
| Weighted average by Cap. | +0.74% | +9.48% | +58.02% | +159.15% |
Employees
-
- Stock Market
- Stocks
- ACOR.Q Stock
- ACOR Stock
Select your edition
All financial news and data tailored to specific country editions
